What is the safety profile of cetirizine in infants younger than one year?

Cetirizine Safety Profile in Infants Under 1 Year

Cetirizine has been demonstrated to be well tolerated and safe in infants aged 6-11 months, with a very good safety profile comparable to placebo, and is specifically distinguished from first-generation antihistamines that have been associated with significant toxicity and fatalities in this age group. 1

Key Safety Evidence

The most compelling safety data comes from prospective, randomized, double-blind, placebo-controlled trials specifically conducted in infants:

Direct Evidence in Infants 6-11 Months

• A dedicated safety study in infants 6-11 months (mean dose 4.5 mg/day, approximately 0.25 mg/kg twice daily) demonstrated no differences in all-cause or treatment-related adverse events between cetirizine and placebo groups 2
• Notably, there was a trend toward fewer adverse events and sleep disturbances in the cetirizine group compared to placebo
• No cardiac effects: No QTc interval prolongation was observed compared to baseline or placebo 2

Extended Safety Data in Young Children (12-24 Months)

• The landmark ETAC study followed 817 children (12-24 months at entry) for 18 months with cetirizine 0.25 mg/kg twice daily 3
• This represents the largest and longest randomized, double-blind, placebo-controlled safety investigation of any H1-antihistamine ever conducted in children
• Drop-outs and serious events (including hospitalizations) were less common in cetirizine-treated children than placebo, though not statistically significant
• No adverse effects on growth, behavior, developmental milestones, neurologic function, cardiovascular parameters, or laboratory values 3
• No QTc prolongation in any child receiving cetirizine 3

Critical Safety Context: Why This Matters

First-Generation Antihistamines Are Dangerous in Infants

The guidelines explicitly warn that between 1969-2006, there were 69 fatalities associated with first-generation antihistamines (diphenhydramine, brompheniramine, chlorpheniramine) in children ≤6 years, with 41 deaths occurring below age 2 years 1. This led to FDA advisory committee recommendations against OTC cough/cold medications in children under 6 years.

Second-Generation Antihistamines Are Different

In stark contrast, second-generation antihistamines including cetirizine "have been shown to be well tolerated and to have a very good safety profile" when used in young children 1. This distinction is critical for clinical decision-making.

Specific Safety Considerations

Somnolence Risk

• Cetirizine may cause mild somnolence at recommended doses (unlike fexofenadine, loratadine, or desloratadine which do not) 1
• However, in the infant studies, somnolence was not increased compared to placebo 2, 3
• In older children (≥12 years), somnolence occurs in approximately 13.7% versus 6.3% with placebo 1

FDA Labeling Limitation

Current FDA labeling for cetirizine indicates approval for ages 6 years and older 4. This creates a gap between regulatory approval and clinical evidence, as the robust safety data exists down to 6 months of age.

Clinical Algorithm for Use in Infants <1 Year

For infants 6-11 months:

1. Cetirizine can be safely used at 0.25 mg/kg twice daily based on high-quality evidence 2, 3
2. Monitor for somnolence at initiation, though risk appears minimal in this age group
3. No cardiac monitoring required (no QTc effects demonstrated)
4. Preferred over first-generation antihistamines, which carry significant mortality risk

For infants <6 months:

• No prospective controlled trial data available
• Use only if benefit clearly outweighs risk, as safety profile is extrapolated rather than proven

Important Caveats

• Off-label use: Despite strong safety evidence, use in infants <6 years remains off-label per FDA labeling 4
• Breast-feeding: Not recommended if breast-feeding per FDA labeling 4
• The safety data, while robust, comes from studies up to 18 months duration; longer-term effects beyond this period have not been systematically studied in infants
• Most adverse events in the trials were attributed to intercurrent infections or allergic disease exacerbations rather than medication effects 3

The evidence strongly supports cetirizine as a safe option in infants ≥6 months when antihistamine therapy is indicated, with a safety profile superior to first-generation agents and comparable to placebo. 2, 3